- Home
- BOOT vs IOVA Comparison
BOOT vs IOVA Comparison
Compare BOOT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | IOVA |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 968.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOOT | IOVA |
|---|---|---|
| Price | $204.52 | $2.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $203.67 | $10.36 |
| AVG Volume (30 Days) | 446.7K | ★ 9.8M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.30 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $2,071,382,000.00 | $250,425,000.00 |
| Revenue This Year | $18.94 | $60.94 |
| Revenue Next Year | $13.11 | $60.85 |
| P/E Ratio | $30.18 | ★ N/A |
| Revenue Growth | 17.82 | ★ 175.62 |
| 52 Week Low | $86.17 | $1.64 |
| 52 Week High | $210.25 | $8.56 |
Technical Indicators
Market Signals| Indicator | BOOT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 46.56 |
| Support Level | $196.35 | $2.18 |
| Resistance Level | $204.39 | $2.32 |
| Average True Range (ATR) | 6.98 | 0.12 |
| MACD | 1.29 | -0.01 |
| Stochastic Oscillator | 78.91 | 18.11 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.